Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR10

The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Immunotherapy

Presenter: Michelle A. Worst, PharmD, BCOP, MBA, Director of Clinical Strategy, Hematology/Oncology, Medscape Oncology

Co-Authors: Haleh Kadkhoda, MS, Executive Director, Strategic Accounts, Medscape Oncology; Jacob Cohen, Manager, Outcomes, Medscape Oncology

BACKGROUND: Ten years after their introduction, immune checkpoint inhibitors are widely used across a variety of tumor types, including melanoma, lung cancer, head and neck cancers, bladder cancer, hepatocellular carcinoma, and renal-cell carcinoma. Within these tumor types, immune checkpoint inhibitors have demonstrated an extension of patient survival. The success of these agents also introduces significant challenges in terms of the role of biomarkers, integration of emerging data into clinical practice, and the identification and management of immune-related adverse events.

OBJECTIVE: To determine if an online continuing education (CE) curriculum consisting of a series of online, video-recorded discussions, developed through the collaboration between Medscape Oncology and the Society for Immunotherapy of Cancer (SITC), could improve pharmacists’ ability in managing patients with solid tumors who are receiving immune checkpoint inhibitors.

METHOD: The analysis used a repeated pairs pre-/post-test study design, in which each individual served as his or her own control. Overall improved learner was assessed from December 2020 to August 2021, by calculating the percentage of learners who gained knowledge or competence, as demonstrated by answering at least 1 more question correctly after CE participation than before. We compared pre- and postassessment scores to determine relative changes in the proportion of correct responses to knowledge or competence questions. McNemar’s chi-square test was used to assess the significance of improvements in knowledge, competence, and confidence.

RESULTS: Statistically significant improvements in knowledge, competence, and confidence were seen after education consumption among participating pharmacists. Pharmacists (N = 22 to 1632) improved their knowledge of immune checkpoint inhibitor mechanisms (P <.001) and clinical trial data (P <.001). The skills to identify patients eligible for immune checkpoint inhibitors also improved (P <.001). Finally, the confidence in using immune checkpoint inhibitors for the treatment of cancer improved (P <.001), as well as coordinating with the interprofessional team (P <.001). This education also resulted in 80% of the pharmacists experiencing an increase in or reinforcement of knowledge or competence from this CE.

CONCLUSION: The use of a series of online, video-recorded discussions was successful in improving the knowledge, competence, and confidence of pharmacists regarding the management of patients who are receiving immune checkpoint inhibitors across solid tumors. These results can translate to improvements in clinical care. We also identified the need for additional educational activities to address residual gaps and further increase pharmacists’ ability in this clinical setting.

Related Items
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Melanoma, Immunotherapy
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Original Article, Lymphoma, Immunotherapy, Infections
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.